Clinical Resources

Belay offers a growing portfolio of CSF liquid biopsy tests for CNS tumor profiling.

Explore our tests →

View our latest news →

Contact our team →

Publications

Clinician perspectives on the clinical utility of Belay Summit™ 2.0 cerebrospinal fluid test – A mixed methods study

The Journal of Liquid Biopsy, June 2026

Analytical Validation of Quantitative Polymerase Chain Reaction and Belay Ascent™ Low-Pass Whole Genome Sequencing to Report on Gene Copy Number Variants in Cerebrospinal Fluid Tumor-Derived DNA

Journal of Molecular Pathology, May 2026

Clinical Validation of the Belay Ascent™ Test to Report on Chromosomal Arm-Level Aneuploidy and Gene-Level Copy Number Variants in Cerebrospinal Fluid Using Low-Pass Whole-Genome Sequencing

Cancers, April 2026

Variant Allelic Frequency to Track Therapy Response and Evaluate Leptomeningeal Disease in Metastatic Central Nervous System Cancers

Diagnostics, March 2026

Clinical Utility of Belay Summit™ Cerebrospinal Fluid Test to Inform Diagnosis and Management of Central Nervous System Cancer—A Single Institution Case Series

Cancers, March 2026

Demonstrating the Impact of the Belay Cerebrospinal Fluid Liquid Biopsy Tests Summit™ and Vantage™ to Inform Diagnosis and Management of Central Nervous System Lymphoma

Lymphatics, February 2026

Analytical Validation and Clinical Sensitivity of the Belay Summit™ 2.0 Cerebrospinal Fluid Liquid Biopsy Test — An Expanded Comprehensive Genomic Profiling Platform for Central Nervous System Malignancies

Cancers, January 2026

Serial Testing of Tumor-Derived DNA in Cerebrospinal Fluid (CSF) to Monitor Leptomeningeal Disease and Assess Therapeutic Response in Lung Cancer Metastasis to the Central Nervous System – A Case Report

Annals of Clinical Case Reports, October 2025

Molecular Analysis of Cerebrospinal Fluid Tumor-Derived DNA to Aid in the Diagnosis and Targeted Treatment of Breast Cancer Brain Metastasis

Diseases, October 2025

Analysis of cerebrospinal fluid (CSF) tumor-derived DNA to obviate biopsy of IDH-mutant brainstem glioma in an adult

The Journal of Liquid Biopsy, September 2025

Analytical Validation and Clinical Sensitivity of the Belay Summit assay for the detection of DNA variants in cerebrospinal fluid (CSF) of primary and metastatic CNS cancer

Journal of Molecular Diagnostics, 2025

Demonstrating the clinical utility of genomic profiling using cerebrospinal fluid to inform management of central nervous system tumors – a meta analysis of the literature

The Journal of Liquid Biopsy, July 2025

Choroid plexus metastasis of a renal cell carcinoma—A case report and review of the literature

Neuro-Oncology Advances, January-December 2025

Analytical validation of the Belay Vantage™ assay for evaluation of MGMT promoter methylation using enzymatically converted tumorDNA from cerebrospinal fluid (CSF)

Cancer Genetics, June 2025

Cerebrospinal Fluid based liquid biopsy to inform diagnosis and management of Leptomeningeal Metastases in EGFR-Mutant Lung Cancer – A Case Report

European Society of Medicine, June 2025

Seq-ing the SINEs of central nervous system tumors in cerebrospinal fluid (CSF)

Cell Reports Medicine, August 2023

Detection of rare mutations, copy number alterations, and methylation in the same template DNA molecules

The Proceedings of the National Academy of Sciences, August 2023

Detection of low-frequency DNA variants by targeted sequencing of the Watson and Crick strands

Nature Biotechnology, October 2021

Detection of tumor-derived DNA in cerebrospinal fluid (CSF) of patients with primary tumors of the brain and spinal cord

Proceedings of the National Academy of Sciences (PNAS), August 2015

Detection of circulating tumor DNA in early- and late-stage human malignancies

Science Translational Medicine, 2014